Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia

Leukemia volume 15, pages 1544–1553 (2001)Cite this article

Abstract

The multidrug resistance proteins (MRPs) MRP1, MRP2, MRP3, MRP5 and P-glycoprotein (P-gp) act in concert with each other to give a net resultant pump function in acute myeloid leukemia (AML). The aim of the present study was to analyze the activity of these proteins, which might be upregulated at relapse as compared with de novo AML due to clonal selection. The mRNA expression and activity of P-gp and the MRPs were determined with RT-PCR and flow cytometry, in conjunction with phenotype, as measured with the monoclonal antibodies CD34, CD38 and CD33, in 30 paired samples of de novo and relapsed AML. P-gp and MRP activity varied strongly between the cases (rhodamine 123 efflux-blocking by PSC833: 5.4 ± 7.7, and carboxyfluorescein efflux-blocking by MK-571: 4.3 ± 6.7, n = 60). P-gp and MRP activity were increased in 23% and 40% of the relapse samples, and decreased in 30% and 20% of the relapse samples, respectively (as defined by a difference of >2 × standard deviation of the assays). Up- or downregulation of mRNA expression was observed for MDR1 (40%), MRP1 (20%), MRP2 (15%), MRP3 (30%), and MRP5 (5%). Phenotyping demonstrated a more mature phenotype in 23% of the relapsed AML cases, and a more immature phenotype in 23% of the relapses, which was independent of the karyotypic changes that were observed in 50% of the studied cases. P-gp and MRP activity correlated with the phenotypic changes, with higher P-gp and MRP activities in less mature cells (r = −0.66, P < 0.001 and r = −0.31, P = 0.02, n = 58). In conclusion, this study shows that P-gp and MRP activity are not consistently upregulated in relapsed AML. However, P-gp and MRP activities were correlated with the maturation stage as defined by immune phenotype, which was observed to be different in 46% of the relapses.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Marie J-P, Zittoun R, Sikic BI . Multidrug resistance (MDR1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity Blood 1991 78: 586–592

    CAS  PubMed  Google Scholar 

  2. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D . Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis Blood 1992 79: 473–476

    CAS  PubMed  Google Scholar 

  3. Guerci A, Merlin HL, Missoun N, Feldmann L, Marchal S, Witz F, Rose C, Guerci O . Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry Blood 1995 85: 2147–2153

    CAS  PubMed  Google Scholar 

  4. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, Mc Connell TS, Head DR, Weick J, Grever MR, Appelbaum FR, Willman CL . Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1 and LRP in acute myeloid leukemia: a southwest Oncology Group Study Blood 1999 94: 1086–1099

    CAS  PubMed  Google Scholar 

  5. Michieli M, Damiani D, Ermacora A, Masolini P, Raspadori D, Visani O, Scheper RJ, Baccarani M . P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications Br J Haematol 1999 104: 328–335

    CAS  PubMed  Google Scholar 

  6. Legrand O, Perrot J-Y, Simonin G, Baudard M, Marie J-P . JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia Blood 2001 97: 502–508

    CAS  PubMed  Google Scholar 

  7. Simon M, Schindler M . Cell biological mechanisms of multidrug resistance in tumor Proc Natl Acad Sci USA 1994 91: 3497–3504

    CAS  PubMed  Google Scholar 

  8. Licht T, Pastan I, Gottesman MM, Hermann F . The multidrug resistance gene in gene therapy of cancer and hematopoietic disorders Ann Hematol 1996 72: 184–193

    CAS  PubMed  Google Scholar 

  9. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG . Overexpression of a novel transporter gene in a multidrug resistance human lung cancer cell line Science 1992 258: 1650–1654

    CAS  PubMed  Google Scholar 

  10. Legrand O, Simonin G, Perrot J-Y, Zittoun R, Marie J-P . Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients Blood 1998 91: 4480–4488

    CAS  PubMed  Google Scholar 

  11. Legrand O, Simonin G, Beauchamp-Nicoud A, Zittoun R, Marie J-P . Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia Blood 1999 94: 1046–1056

    CAS  PubMed  Google Scholar 

  12. Van der Kolk DM, de Vries EGE, van Putten WLJ, Verdonck LF, Ossenkoppele GJ, Verhoef EG, Vellenga E . P-gp and MRP activities in relation to treatment outcome in acute myeloid leukemia Clin Cancer Res 2000 6: 3205–3214

    CAS  PubMed  Google Scholar 

  13. Marbeuf-Gueye C, Broxterman HJ, Dubru F, Priebe W, Garnier-Suillerot A . Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells Mol Pharmacol 1998 53: 141–147

    CAS  PubMed  Google Scholar 

  14. Loe DW, Almquist KC, Deeley RG, Cole SPC . Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport J Biol Chem 1996 271: 9675–9682

    CAS  PubMed  Google Scholar 

  15. Renes J, de Vries EGE, Nienhuis EF, Jansen PLM, Müller M . ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1 Br J Pharmacol 1999 126: 681–688

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, Kagotani K, Okumura K, Akiyama S, Kuwano M . A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplain-resistant human cancer cell lines with decreased drug accumulation Cancer Res 1996 56: 4124–4129

    CAS  PubMed  Google Scholar 

  17. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk M, Juijn JA, Baas F, Borst P . Analysis of expression of cMOAT (MRP2), MRP3, MRP4 and MRP5, homologs of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines Cancer Res 1997 57: 3537–3547

    CAS  PubMed  Google Scholar 

  18. Kool M, van der Linden M, de Haas M, Baas F, Borst P . Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells Cancer Res 1999 59: 175

    CAS  PubMed  Google Scholar 

  19. Hopper E, Belinsky MG, Zeng H, Tosolini A, Testa JR, Kruh GD . Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily Cancer Lett 2001 162: 181–191

    CAS  PubMed  Google Scholar 

  20. Keppler D, Cui Y, Koning J, Leier I, Nies A . Export pumps for anionic conjugates encoded by MRP genes Adv Enzyme Regul 1999 39: 237–246

    CAS  PubMed  Google Scholar 

  21. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree ML, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, Oude Elferink RPJ, Baas F, Borst P . MRP3, an organic anion transporter able to transport anti-cancer drugs Proc Natl Acad Sci USA 1999 96: 6914–6919

    CAS  PubMed  Google Scholar 

  22. Lee K, Klein-Szanto AJ, Kruh GD . Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells J Natl Cancer Inst 2000 92: 1934–1940

    CAS  PubMed  Google Scholar 

  23. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, Fridland A . MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs Nat Med 1999 5: 1048–1051

    CAS  PubMed  Google Scholar 

  24. Wijnholds J, Mol CAAM, van Deemter L, de Haas M, Scheffer GL, Baas F, Beijnen JH, Scheper RJ, Hatse S, De Clerq E, Balzarini J, Borst P . Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs Proc Natl Acad Sci USA 2000 97: 7476–7481

    CAS  PubMed  Google Scholar 

  25. Jedlitschky G, Burchell B, Keppler D . The multidrug resistance protein 5 (MRP5) functions as an ATP-dependent export pump for cyclic nucleotides J Biol Chem 2000 275: 30069–30074

    CAS  PubMed  Google Scholar 

  26. Funke I, Wiesneth M, Platow S, Kubanek B . Palliative cytoreduction in refractory acute leukemia: a retrospective study of 57 adult patients Ann Hematol 2000 79: 132–137

    CAS  PubMed  Google Scholar 

  27. Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Omoto E, Kuriyama K, Hatake K, Saito K, Kanamaru A, Oh H, Ohtake S, Asou N, Sakamaki H, Yamada O, Jinnai I, Tsubaki K, Takeyama K, Hiraoka A, Matsuda S, Takahashi M, Shimazaki C, Adachi K, Kageyama S, Ohno R et al. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group Int J Hematol 1999 70: 97–104

    CAS  PubMed  Google Scholar 

  28. Coulthard SA, Howell C, Robson J, Hall AG . The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia Blood 1998 92: 2856–2862

    CAS  PubMed  Google Scholar 

  29. Mayer JR, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E . Third intensive postremission chemotherapy in adults with acute myeloid leukemia New Engl J Med 1994 331: 896–903

    CAS  PubMed  Google Scholar 

  30. Cassileth PA, Lynch E, Hines JD . Varying intensity of postremission therapy in acute myeloid leukemia Blood 1993 79: 1924–1930

    Google Scholar 

  31. Schiller G, Gajewski J, Territo M . Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia Blood 1992 80: 2977–2982

    CAS  PubMed  Google Scholar 

  32. Cassileth PA, Harrington DP, Appelbaum FR, Hillard ML, Rowe JM, Paiette E, Willman C, Hurd DD, Bennett JM, Blume KG, Head DR, Wiernik PH . Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission New Engl J Med 1998 339: 1649–1656

    CAS  PubMed  Google Scholar 

  33. Godwin JE, Kopecky KJ, Head DR . A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study (9031) Blood 1998 15: 3607–3615

    Google Scholar 

  34. Löwenberg B, Van Putten WLJ, Verdonck LF . Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study J Clin Oncol 1990 8: 287–294

    PubMed  Google Scholar 

  35. Burnett AK, Transey P, Watkins R . Transplantation of unpurged autologous bone-marrow in acuate myeloid leukaemia in first remission Lancet 1984 2: 1068–1070

    CAS  PubMed  Google Scholar 

  36. Lyttelton MP, Hart S, Ganeshaguru K, Hoffbrand AV, Mehta AB . Quantitation of multidrug resistant MDR1 transcript in acute myeloid leukaemia by non-isotopic quantitative cDNA polymerase chain reaction Br J Haematol 1994 86: 540–546

    CAS  PubMed  Google Scholar 

  37. Beck J, Handgretinger R, Klingebiel T, Dopfer R, Schaich M, Ehninger G, Niethammer D, Gekeler V . Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML Leukemia 1996 10: 423–433

    Google Scholar 

  38. Zhou DC, Zittoun R, Marie JP . Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia Leukemia 1995 9: 1661–1665

    CAS  PubMed  Google Scholar 

  39. Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ, Kaufmann SH . Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia Blood 1995 85: 186–193

    CAS  PubMed  Google Scholar 

  40. Estey E, Keating MJ, Pierce S, Stass S . Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia Leukemia 1995 9: 972–977

    CAS  PubMed  Google Scholar 

  41. Garson OM, Hagemeijer A, Sakurai M, Reeves BR, Swansbury GJ, Williams GJ, Alimena G, Arthur DC, Berger R, de la Chapelle A . Cytogenetic studies of 103 patients with acute myelogenous leukemia in relapse Cancer Genet Cytogenet 1989 40: 187–202

    CAS  PubMed  Google Scholar 

  42. Van der Kolk DM, Vellenga E, van der Veen AY, Noordhoek L, Timmer-Bosscha H, Ossenkoppele GJ, Raymakers RA, Müller M, van den Berg E, de Vries EGE . Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity Blood 2000 95: 3514–3519

    CAS  PubMed  Google Scholar 

  43. Te Boekhorst PAW, de Leeuw K, Schoester M, Wittebol S, Nooter K, Hagemeyer A, Löwenberg B, Sonneveld P . Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells Blood 1993 82: 3157–3162

    CAS  PubMed  Google Scholar 

  44. Gralnick HR . Classification of acute leukemia Ann Intern Med 1977 87: 740

    Google Scholar 

  45. Van der Kolk DM, de Vries EGE, Koning JA, van den Berg E, Müller M, Vellenga E . Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines and normal hematopoietic CD34+ peripheral blood cells Clin Cancer Res 1998 4: 1727–1736

    CAS  PubMed  Google Scholar 

  46. Jones TR, Zamboni R, Belley M, Champion E, Charette L, Ford-Hutchinson AW, Frenette R, Gauthier J-Y, Leger S, Masson P, McFarlane S, Piechuta H, Rokach J, Williams H, Young RN . Pharmacology of L-660, 711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist Can J Physiol Pharmacol 1989 67: 17–28

    CAS  PubMed  Google Scholar 

  47. Löwenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de cataldo R, Dekker AW, Berneman ZN, Thyss A, Van der Lelie J, Sonneveld P, Visani G, Fillet G, Hayat M, Hagemeijer A, Solbu G, Zittoun R . Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy—the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch–Belgian Hemato-Oncology Cooperative Hovon Group J Clin Oncol 1998 15: 872–881

    Google Scholar 

  48. Vellenga E, van Putten WLJ, Boogaerts MA, Daenen SMGJ, Verhoef GEG, Hagenbeek A, Jonkhoff AR, Huijgens PC, Verdonck LF, van der Lelie J, Schouten HC, Gmür J, Wijermans P, Gratwohl A, Hess U, Fey MF, Löwenberg B . Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia Bone Marrow Transplant 1999 23: 1279–1282

    CAS  PubMed  Google Scholar 

  49. Keppler D, Cui Y, Konig J, Leier I, Nies A . Export pumps for anionic conjugates encoded by MRP genes Adv Enzyme Regul 1999 39: 237–246

    CAS  PubMed  Google Scholar 

  50. Cantz T, Nies AT, Brom M, Hofmann AF, Kepper D . MRP2, a human conjugate export pump, is present and transports fluo 3 into apical vacuole of Hep G2 cells Am J Physiol Gastrointest Liver Physiol 2000 278: G522–G531

    CAS  PubMed  Google Scholar 

  51. Barhoumi R, Bowen JA, Stein LS, Echols J, Burghardt RC . Concurrent analysis of intracellular glutathione content and gap junctional intercellular communication Cytometry 1993 14: 747–756

    CAS  PubMed  Google Scholar 

  52. Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M . Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia J Clin Oncol 1997 15: 1796–1802

    CAS  PubMed  Google Scholar 

  53. Advani R, Visani G, Milligan D, Saba H, Tallman M, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Covelli A, Sikic B, Greenberg P . Treatment of poor prognosis AML patients using PSC833 (valdospar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC) Adv Exp Med Biol 1999 457: 47–56

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by a grant of the Foundation of Pediatric Oncology Groningen (SKOG 99–01).

Author information

Authors and Affiliations

  1. Division of Hematology, University Hospital of Groningen, The Netherlands

    DM van der Kolk & E Vellenga

  2. Division of Medical Oncology, University Hospital of Groningen, The Netherlands

    DM van der Kolk & EGE de Vries

  3. Division of Gastroenterology and Hepatology, University Hospital of Groningen, The Netherlands

    M Müller

  4. Department of Medical Genetics, University Groningen, The Netherlands

    L Noordhoek & E van den Berg

  5. Division of Hematology, Medical Center Free University, Amsterdam, The Netherlands

    MA van der Pol

Authors
  1. DM van der Kolk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. EGE de Vries
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Noordhoek
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E van den Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. MA van der Pol
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E Vellenga
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

van der Kolk, D., de Vries, E., Noordhoek, L. et al. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia 15, 1544–1553 (2001). https://doi.org/10.1038/sj.leu.2402236

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402236

Keywords

This article is cited by

Search

Advanced search

Quick links